MeiraGTx Reports Fourth Quarter and Full Year 2020 Financial and Operational Results
March 11, 2021 08:00 ET
|
MeiraGTx
- Preparing to Initiate Phase 3 Lumeos Clinical Trial in AAV-RPGR- Announced Positive Preliminary Clinical Data from AQUAx AAV-hAQP1 Phase 1 Trial for Treatment of Grade 2/3 Xerostomia- Completed...
MeiraGTx to Present at the 2021 Barclays Global Healthcare Conference
March 04, 2021 08:30 ET
|
MeiraGTx
LONDON and NEW YORK, March 04, 2021 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced that Alexandria...
MeiraGTx Announces AAV-CNGA3 Granted Fast Track Designation by U.S. FDA for Treatment of Achromatopsia
January 26, 2021 08:30 ET
|
MeiraGTx
LONDON and NEW YORK, Jan. 26, 2021 (GLOBE NEWSWIRE) -- MeiraGTx Holdings Plc (NASDAQ:MGTX), a vertically integrated, clinical stage gene therapy company, today announced that the U.S. Food and Drug...
MeiraGTx To Present Clinical Program Update for AAV-hAQP1 Treatment of Radiation-Induced Xerostomia
December 16, 2020 16:30 ET
|
MeiraGTx
LONDON and NEW YORK, Dec. 16, 2020 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced the Company will...
MeiraGTx to Participate in the Evercore ISI 3rd Annual HealthCONx Conference
November 30, 2020 16:30 ET
|
MeiraGTx
LONDON and NEW YORK, Nov. 30, 2020 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced that Alexandria Forbes,...
MeiraGTx to Participate in the Piper Sandler 32nd Annual Virtual Healthcare Conference
November 23, 2020 16:30 ET
|
MeiraGTx
LONDON and NEW YORK, Nov. 23, 2020 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced that Alexandria...
MeiraGTx Announces Pricing of Public Offering of Ordinary Shares
November 19, 2020 07:00 ET
|
MeiraGTx
LONDON and NEW YORK, Nov. 19, 2020 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq:MGTX), a vertically integrated, clinical stage gene therapy company, today announced the pricing of an...
MeiraGTx Announces Proposed Public Offering of Ordinary Shares
November 18, 2020 16:25 ET
|
MeiraGTx
LONDON and NEW YORK, Nov. 18, 2020 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (NASDAQ:MGTX), a vertically integrated, clinical stage gene therapy company, today announced that it has...
MeiraGTx Announces Investigational Gene Therapy Continues to Demonstrate Statistically Significant Improvement in Vision in Patients with X-Linked Retinitis Pigmentosa One Year After Treatment
November 13, 2020 17:55 ET
|
MeiraGTx
LONDON and NEW YORK, Nov. 13, 2020 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced 12-month data from the...
MeiraGTx to Present at the Barclays Gene Editing & Gene Therapy Summit
November 10, 2020 16:30 ET
|
MeiraGTx
LONDON and NEW YORK, Nov. 10, 2020 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced that Alexandria...